CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CD47 expression is critical for CAR T-cell survival in vivo.
CD47 expression is critical for CAR T-cell survival in vivo.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些发现强调,CD47 表达对 CAR-T 细胞在体内存活至关重要,并且是过继性 T 细胞治疗成功的必要条件。
CD47在多种实体瘤中高表达,是一个有吸引力的免疫治疗靶点。然而,T细胞也表达CD47。针对CD47-CAR-T 细胞的研究有限,CD47在CAR-T 细胞功能中的作用仍很大程度上未知。
本文介绍以高亲和力信号调节蛋白变体CV1为基础开发CD47-CAR-T 细胞;CV1可结合CD47。采用人外周血单个核细胞制备CV1-CAR-T 细胞,并在体内外进行评估。通过敲除T细胞中的CD47并进行下游功能分析,考察CD47对CAR-T 细胞功能的作用。
虽然CV1-CAR-T 细胞具有特异性且体外活性强,但在异种移植模型中不具备抗肿瘤活性。机制研究发现,CV1-CAR-T 细胞下调CD47以避免同类相残,但CD47丢失会导致其无法在体内扩增和持续存留。这种效应并不限于CV1-CAR-T 细胞,因为靶向另一种实体瘤抗原的CD47敲除CAR-T 细胞在体内也出现相同结局。此外,CD47敲除T细胞易受巨噬细胞介导的吞噬作用影响。
这些发现凸显CD47表达对CAR-T 细胞在体内存活至关重要,是成功过继T细胞疗法不可或缺的条件。
CD47 is an attractive immunotherapeutic target because it is highly expressed on multiple solid tumors. However, CD47 is also expressed on T cells. Limited studies have evaluated CD47-chimeric antigen receptor (CAR) T cells, and the role of CD47 in CAR T-cell function remains largely unknown.
Here, we describe the development of CD47-CAR T cells derived from a high affinity signal regulatory protein variant CV1, which binds CD47. CV1-CAR T cells were generated from human peripheral blood mononuclear cells and evaluated in vitro and in vivo. The role of CD47 in CAR T-cell function was examined by knocking out CD47 in T cells followed by downstream functional analyses.
While CV1-CAR T cells are specific and exhibit potent activity in vitro they lacked antitumor activity in xenograft models. Mechanistic studies revealed CV1-CAR T cells downregulate CD47 to overcome fratricide, but CD47 loss resulted in their failure to expand and persist in vivo. This effect was not limited to CV1-CAR T cells, since CD47 knockout CAR T cells targeting another solid tumor antigen exhibited the same in vivo fate. Further, CD47 knockout T cells were sensitive to macrophage-mediated phagocytosis.
These findings highlight that CD47 expression is critical for CAR T-cell survival in vivo and is a 'sine qua non' for successful adoptive T-cell therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。